Michael Mingueneau PhD

Michael Mingueneau is the Senior Vice President and Head of Immunology at Sail, where his responsibilities have included establishing a comprehensive understanding of the immunological properties of SAIL’s eRNA platform while building out the company’s immunology unit and pipeline. As part of SAIL’s vision to fully unlock the potential of programmable RNA medicines as a therapeutic modality, the immunology group at SAIL, led by Michael, aims to transform the care of patients with immunological diseases by leveraging SAIL’s innovative RNA and delivery technology platforms. Michael is an immunologist and drug discovery leader with experience in peripheral autoimmunity, neuroinflammation, and immuno-oncology.

Michael joined Sail from Biogen, where he held positions of increasing responsibility in the Immunology, Multiple Sclerosis, and Neuroimmunology departments over a period of ten years. At Biogen, as the Head of the Immunology and Neuroimmunology unit, he led the advancement of several antibody and small molecule programs from early discovery to R2D transition/Ph. 1, including BIIB091, a BTK inhibitor currently in phase 2 trial in Multiple Sclerosis patients. In this role, Michael’s unit also supported late-stage MS and immunology assets and in-line products. Before Biogen, Michael completed his postdoctoral training in the laboratories of Drs. C. Benoist and D. Mathis (Harvard Medical School, Boston, US) following a Ph.D. in Immunology with Drs. B. and M. Malissen (CIML & Aix-Marseille University, France). Michael’s work has resulted in publications in Nature Immunology, Immunity, Science, Blood, Journal of Exp Medicine, Journal of Allergy and Clinical Immunology, among others.